e-Drug3D

2082

LENIOLISIB

INN
LENIOLISIB

cas 1354690-24-6

CLASS

ANTINEOPLASTIC
KINASE INHIBITOR INDICATED FOR THE TREATMENT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) SYNDROME (APDS)

ROUTE (list)

ORAL

ATC code

L03AX22

PK parameters

Tmax 1 HOUR
VD 28.5 LITER
PPB 94.5 PERCENT
t1/2 10 HOUR

Solubility

DECREASING SOLUBILITY OBSERVED WITH INCREASING PH

Target

TARGET PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA)

PDB
5O83 (DISCOVERY OF CDZ173 (LENIOLISIB), REPRESENTING A STRUCTURALLY NOVEL CLASS OF PI3K DELTA-SELECTIVE INHIBITORS)

Download experimental 3D coordinates of 9NQ with added hydrogens

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PK3CD UNIPROT O00329

Download SDF file

1-Propanone, 1-[(3S)-3-[[5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin-4-yl]amino]-1-pyrrolidinyl]- (ACI)

Formula:
C21H25F3N6O2

Calculated chemical properties:

MW 450.47
NB_atoms 32
XLogP 2.88
PSA 74.759
NB_HD 1
NB_HA 8
fsp3 0.52
Lipinski(0=no;1=yes) 1

FDA
NDA 217759 (label) INN (LENIOLISIB PHOSPHATE) JOENJA (PHARMING) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY